More on Sequestration and the FDA Budget for FY 13

Sep 10

Written By

An article on Bloomberg Businessweek this morning offers additional information on the potential threat that sequestration presents to the FDA's budge for 2013.Entitled "FDA drug review deal set to unravel as fiscal cliff looms," the article includes comments from Karen Riley at the FDA, from Steven Grossman of the Alliance, and from Alan Goldhammer (an independent pharmaceutical industry consultant).

More on Sequestration and the FDA Budget for FY 13

Hamburg Speaks on Effect of Sequester on User Fees

Of 6-Month CRs and the Perils of Sequestration